On May 17, 2021, the U.S. Department of Justice (“DOJ”) announced the establishment of a COVID-19 Fraud Enforcement Task Force (“Task Force”) to ramp up enforcement efforts against COVID-19-related fraud.[1]

Organized and led by Deputy Attorney General Lisa Monaco, the Task Force convened its first meeting on May 28 and aims to “marshal the resources of the [DOJ] in partnership with agencies across government to enhance enforcement efforts against COVID-19 related fraud.”[2]  The Task Force will involve coordination among several DOJ components, including the Criminal and Civil Divisions, the Executive Office for United States Attorneys, and the Federal Bureau of Investigation.  “Key interagency partners” have also been invited to join the Task Force, including the Department of Labor, the Department of the Treasury, the Department of Homeland Security, the Social Security Administration, the Department of Veterans Affairs, the Food and Drug Administration’s Office of Criminal Investigations, the U.S. Postal Inspection Service, the Small Business Administration, the Special Inspector General for Pandemic Relief, and Pandemic Response Accountability Committee, among others.

In a DOJ memorandum accompanying the announcement, Attorney General Merrick Garland identified three key goals of the Task Force: “(1) to identify cross-governmental resources, investigative techniques, and information for uncovering fraud schemes and the actors who perpetrate them; (2) to harness what [DOJ has] learned about COVID-19 related and other types of fraud from past efforts; and (3) to deter, detect, and disrupt future fraud wherever it occurs.”[3]  The memorandum also notes how the Task Force will enhance DOJ’s “public awareness campaign” focusing on educating “individuals and businesses about the threat of COVID-19 related fraud” and raising awareness on “how whistleblowers can report corporate fraud.”[4]

According to DOJ, the need to combat widespread fraud relating to COVID-19 relief programs drove the establishment of the Task Force (our recent coverage of DOJ’s COVID-19-related enforcement activity can be found here and here).  Examples described in Attorney General Garland’s memorandum include selling counterfeit vaccines and personal protective equipment, inflating payrolls to obtain larger loans from the U.S. government, and fraudulently misrepresenting the products or services being sold to the U.S. government, among other things.[5]  Indeed, during its first meeting last week, the Task Force’s discussion of “priority goals” included “increased efforts to combat fraud related to COVID-19 relief programs like the Paycheck Protection Program (PPP), the Economic Injury Disaster Loan (EIDL) program, as well as unemployment insurance benefits.”[6]  The Task Force’s initial meeting also focused on increasing enforcement efforts to combat COVID-19-related health care fraud, including discussion of DOJ’s pursuit of criminal charges against 14 defendants for alleged participation in fraudulent schemes across six states, which DOJ announced last week.[7]

The White House has also expressed support for the Task Force.  On May 17, President Biden released a statement welcoming the establishment of the Task Force, highlighting the importance of “fastidious oversight” over the American Rescue Plan and other pandemic relief measures, and explaining how, through the Task Force, DOJ “will work with other agencies to investigate and prosecute domestic and international criminals intent on exploiting relief programs for personal and financial gain – and recover stolen funds.”[8]

A primary tool in DOJ’s health care cases, the Task Force will likely leverage information from multiple federal agencies to investigate COVID-19-related fraud through enhanced data analytics.  With improved interagency coordination, and the Task Force marshaling the investigative efforts, we expect a continued uptick in criminal and civil enforcement activity in the coming months.  As we previously covered in connection with DOJ’s first reported False Claims Act (“FCA”) settlement to resolve allegations of CARES Act fraud, DOJ has signaled its early intent to use the FCA as a tool to address COVID-19-related fraud.  Individuals and businesses that have received relief funds should therefore expect enhanced scrutiny from government agencies and be prepared to demonstrate that relief funds were obtained and disbursed in accordance with the terms and conditions of the relevant relief program.

[1] Press Release, U.S. Department of Justice, Attorney General Announces Task Force to Combat COVID-19 Fraud (May 17, 2021), available at https://www.justice.gov/opa/pr/attorney-general-announces-task-force-combat-covid-19-fraud.

[2] Id.; Press Release, U.S. Department of Justice, Deputy Attorney General Convenes Inaugural Meeting of the COVID-19 Fraud Enforcement Task Force (May 28, 2021), available at https://www.justice.gov/opa/pr/deputy-attorney-general-convenes-inaugural-meeting-covid-19-fraud-enforcement-task-force.

[3] Memorandum for the Deputy Attorney General, Heads of Department Litigating Components, United States Attorneys, Executive Office for United States Attorneys, Federal Bureau of Investigation, Office of the Inspector General, Organized Crime Drug Enforcement Task Force, and Interpol Washington from the Attorney General, at 2 (May 17, 2021), available at https://www.justice.gov/opa/press-release/file/1394721/download.

[4] Id. at 3.

[5] Id. at 1.

[6] See supra note 2.

[7] Press Release, U.S. Department of Justice, DOJ Announces Coordinated Law Enforcement Action to Combat Health Care Fraud Related to COVID-19 (May 26, 2021), available at https://www.justice.gov/opa/pr/doj-announces-coordinated-law-enforcement-action-combat-health-care-fraud-related-covid-19.

[8] Statement of President Joe Biden on American Rescue Plan Oversight (May 17, 2021), available at https://www.whitehouse.gov/briefing-room/statements-releases/2021/05/17/statement-of-president-joe-biden-on-american-rescue-plan-oversight/.

Back to Health Law Advisor Blog

Search This Blog

Blog Editors

Authors

Related Services

Topics

Archives

Jump to Page

Subscribe

Sign up to receive an email notification when new Health Law Advisor posts are published:

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.